Prognostic Biomarker Testing in CLL/SLL Remains Low
Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.
Diagnosis & Disease Information
Hospitalization Burden of Patients With Multiple Myeloma
Hospitalization due to MM has increased over the last 10 years, but in-hospital mortality has declined.
Liso-Cel Plus Ibrutinib Demonstrated Efficacy in R/R CLL/SLL
A phase 1 trial demonstrated antitumor activity of liso-cel plus ibrutinib with low rates of grade 3 or higher CRS and neurotoxicity among heavily pretreated patients with CLL/SLL.
Bispecific CAR-T Therapy Found to Have Promising Efficacy in Older Patients With R/R B-Cell NHL
The bispecific CAR-T therapy targets CD20 and CD19.
Fixed Duration Ibrutinib-Venetoclax for CLL Resulted in High Rate of Undetectable MRD
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.
Hematopoietic Stem Cell Transplantation May Not Reduce Renal Function in Sickle Cell Disease
For patients with sickle cell disease, HSCT may not be associated with a significant increase in CKD incidence or prevalence following transplantation.
Azacitidine vs Decitabine in Unfit, Newly Diagnosed Acute Myeloid Leukemia
Investigators compared clinical outcomes between unfit patients with newly diagnosed AML who were treated with either azacitidine or decitabine.
Decitabine With Venetoclax as Salvage Therapy in R/R Acute Myeloid Leukemia
For younger patients with relapsed or refractory AML, the use of decitabine with venetoclax may be an appropriate salvage therapy, and is comparable to intensive chemotherapy regimens.
BCMA-Directed CAR-T Therapy Shows Clinical Activity in Multiple Myeloma
A CAR-T therapy that targets B-cell maturation antigen showed clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma.
Duvelisib Had Consistent Response Rates in R/R Peripheral T-Cell Lymphoma
Response appears to be consistent across histological subtypes.
- Loading...
Loading...
Loading... 
Loading...